In outpatients with schizophrenia who received CBSST, oxytocin (36 IU twice daily) gave no additive benefit for social cognition over placebo with CBSST.
In plain wordsIn people with schizophrenia having social skills training, oxytocin added no benefit for social cognition compared with placebo.
- Peptide
- Oxytocin
- Outcome
- No significant changeSocial cognition, added benefit of oxytocin beyond CBSST
- Study
n = 62
- Comparator
- Placebo plus CBSST
- Outcome group
- Cognition and memory · Mental health and mood
- Studied dose
- 36 IU twice daily · 24 weeksAs given in this study (human).
Source sentences
there was no additive benefit of oxytocin beyond the effects of CBSST alone.
2 context sentences(design, population, supporting numbers)
The current study tested this hypothesis in a 24-week (48 session) double-blind, placebo-controlled trial that combined oxytocin and Cognitive-Behavioral Social Skills Training (CBSST), which included elements from Social Cognition and Interaction Training (SCIT).
Participants included 62 outpatients diagnosed with schizophrenia (placebo n = 31; oxytocin n = 31) who received 36 IU BID, with supervised administration 45 min prior to sessions on CBSST group therapy days.